Longitudinal profiling of the gut microbiome in patients with psoriatic arthritis and ankylosing spondylitis: a multicentre, prospective, observational study
Abstract Background Psoriasis is a chronic inflammatory disease of the skin affecting 2–3% of UK population. 30% of people affected by psoriasis will develop a distinct form of arthritis within 10 years of the skin condition onset. Although the pathogenesis of psoriatic arthritis is still unknown, t...
Main Authors: | Jesus Miguens Blanco, Federica Borghese, Neil McHugh, Peter Kelleher, Raj Sengupta, Julian R. Marchesi, Sonya Abraham |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-11-01
|
Series: | BMC Rheumatology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s41927-020-00155-2 |
Similar Items
-
Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept
by: Viola Sacchi, et al.
Published: (2010-06-01) -
Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016-10-01) -
Comparative analysis between ankylosing spondylitis and axial psoriatic arthritis patients
by: Marwa Mahmoud Abdelaziz, et al.
Published: (2022-01-01) -
Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis
by: Elena Conesa-Nicolás, et al.
Published: (2021-01-01) -
Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
by: M. Rossini, et al.
Published: (2015-03-01)